Recombinant HCMV and RHCMV vectors and uses thereof
AssigneeOregon Health & Science University
InventorsLouis Picker, Jay A. Nelson, Klaus Frueh, Michael A. Jarvis, Scott G. Hansen
Life of this patent
Estimating the term…
Abstract
The present invention relates to recombinant rhesus cytomegalovirus (RhCMV) and human cytomegalovirus (HCMV) vectors encoding heterologous antigens, such as pathogen-specific antigens or tumor antigens, which may be used, for example, for the treatment or prevention of infectious disease or cancer. The recombinant RhCMV or HCMV vectors elicit and maintain high level cellular immune responses specific for the heterologous antigen while including deletions in one or more genes essential or augmenting for CMV replication, dissemination or spread.
Claims24
A recombinant viral vector comprising a nucleic acid sequence encoding a human cytomegalovirus (HCMV) backbone vector and at least one human immunodeficiency virus (HIV)-derived antigen,
- wherein the recombinant viral vector:
- (a) comprises a deletion in gene UL82 that eliminates expression of a functional pp71 protein, (b) is deficient in host to host spread, (c) infects a HCMV seropositive host upon administration of said recombinant viral vector, and (d) induces and maintains a long-term effector memory T cell response to the at least one HIV-derived antigen in said seropositive host.
A recombinant viral vector comprising a nucleic acid sequence encoding a rhesus cytomegalovirus (RhCMV) backbone vector and at least one simian immunodeficiency virus (SIV)-derived antigen,
- wherein the recombinant viral vector:
- (a) comprises a deletion in gene Rh110 that eliminates expression of a functional pp71 protein, (b) is deficient in host to host spread, (c) infects a RhCMV seropositive host upon administration of said recombinant viral vector, and (d) induces and maintains a long-term effector memory T cell response to the at least one SIV-derived antigen in said seropositive host.
A recombinant viral vector comprising a nucleic acid sequence encoding a HCMV backbone vector and at least one HIV Gag epitope, wherein the recombinant viral vector:
- (a) comprises a deletion in gene UL82 that eliminates expression of a functional pp71 protein, (b) is deficient in host to host spread, (c) infects a HCMV seropositive host upon administration of said recombinant viral vector, and (d) induces and maintains a long-term effector memory T cell response to HIV Gag.
Dependencies are inferred from the claim text.